Dipeptidylpeptidase-4 (DPP4) inhibitors and Glucagon-like peptide-1 receptor agonist (GLP-1RAs) are important treatments for T2D.These medicines may increase the risk of pancreatitis [36, 37]. This evidence concerns the gene GLP1R and pancreatitis.